Manufacturers are having issues with yields from strains used to produce H1N1 vaccines, says Rhenu Bhuller, global VP of pharmaceuticals at Frost & Sullivan. She sheds light on what is happening, with guest host, Greg Bundy of AIMS Finance & CNBC's Martin Soong.
Topics:
Pharmaceuticals | Analyst | PharmaceuticalsHealth Care
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT